The Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) has recommended to the European Medicines Agency in its last meeting the approval of the French Valneva vaccine as a booster dose. The beneficiaries will be adult patients from 18 to 50 years of age.
Valneva’s Serum it was the sixth approved by the European Medicines Agency, specifically in June 2022. It is a purified and adjuvanted serum that contained the complete Covid virus, although inactivated. The CHMP concluded that the serum met the European Union criteria for efficacy, safety and quality. A month before its approval, the European Commission decided to break the contract for the purchase of vaccines against Covid 19 that it had with the French company from which it had pre-purchased 60 million doses. The other five that received the green light before this one were Pfizer, Moderna, AstraZeneca, Janssen and Novavax.
Despite the recommendation of the technicians of the European Medicines Agency, the commercial route of this serum is complicated in Europe. In fact, for example, Spain has not inoculated a single dose since its approval more than six months ago. The reason is in the decision of the Executive of Ursula Von der Leyen, who broke the agreement because the French company did not deliver on time the documentation that the EMA had demanded.
Four days before the Valneva vaccine was approved, the multinational giant Pfizer announced an investment of 90 million euros in the French company. The project that moved the managers of the American had nothing to do with the Covid. They were interested in a possible vaccine against Lyme disease, a disease caused by a bacterium transmitted by ticks. Pfizer would be in charge of taking the antigen to the last phase of the clinical trial, that is, phase three, and from there, negotiating its commercialization with the regulatory agencies.
